Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKDB-501A vs Botox for Moderate-to-Severe Glabellar Lines
NCT05804656Phase 3Completed
- Sponsor
- CKD BiO
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Microbial Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of CKDB-501 in glabellar lines, sponsored by CKD BiO. Started Apr 2023; status: completed.
02
Drugs
CKDB-501
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05804656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804656.